quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:05:00·59d
PRRelease
Summit Therapeutics Inc. logo

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

SMMT· Summit Therapeutics Inc.
Health Care
Original source

Companies

  • SMMT
    Summit Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 8UpdateStifel$45.00
  • Mar 16UpdateJefferies$15.00
  • Dec 17UpdateBarclays$18.00
  • Nov 18UpdateWolfe Research-
  • Sep 17UpdateBarclays$13.00
  • Sep 4UpdateGuggenheim$40.00

Related

  • SEC6d
    SEC Form DEFA14A filed by Summit Therapeutics Inc.
  • SEC6d
    SEC Form DEF 14A filed by Summit Therapeutics Inc.
  • ANALYST15d
    Stifel initiated coverage on Summit Therapeutics with a new price target
  • SEC17d
    SEC Form PRE 14A filed by Summit Therapeutics Inc.
  • PR27d
    Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
  • ANALYST38d
    Summit Therapeutics downgraded by Jefferies with a new price target
  • PR56d
    Summit Therapeutics to Present at Upcoming Investor Conferences
  • SEC59d
    SEC Form S-8 filed by Summit Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022